Overview
flowchart TD
companies_inhibikase["Inhibikase Therapeutics"]
style companies_inhibikase fill:#4fc3f7,stroke:#333,color:#000
companies_inhibikase_0["Company Profile"]
companies_inhibikase -->|"includes"| companies_inhibikase_0
style companies_inhibikase_0 fill:#81c784,stroke:#333,color:#000
companies_inhibikase_1["Technology Platform"]
companies_inhibikase -->|"includes"| companies_inhibikase_1
style companies_inhibikase_1 fill:#ef5350,stroke:#333,color:#000
companies_inhibikase_2["c-Abl Tyrosine Kinase Inhibition"]
companies_inhibikase -->|"includes"| companies_inhibikase_2
style companies_inhibikase_2 fill:#ffd54f,stroke:#333,color:#000
companies_inhibikase_3["Chemical Biology Approach"]
companies_inhibikase -->|"includes"| companies_inhibikase_3
style companies_inhibikase_3 fill:#ce93d8,stroke:#333,color:#000
companies_inhibikase_4["Clinical Pipeline"]
companies_inhibikase -->|"includes"| companies_inhibikase_4
style companies_inhibikase_4 fill:#4fc3f7,stroke:#333,color:#000
companies_inhibikase_5["IkT-148009 Lead Program"]
companies_inhibikase -->|"includes"| companies_inhibikase_5
style companies_inhibikase_5 fill:#81c784,stroke:#333,color:#000
...
Overview
Mermaid diagram (expand to render)
Inhibikase Therapeutics (NASDAQ: IKT) is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Parkinson's disease and other neurodegenerative disorders. The company's lead program targets the c-Abl tyrosine kinase pathway, which has been implicated in neuronal dysfunction and alpha-synuclein pathology in Parkinson's disease. [@inhibikase]
Company Profile | Attribute | Details |Headquarters | Boston, Massachusetts, USA |Founded | 2010 |CEO | Milton Werner, PhD |Market Cap | ~$50 million (2024) |Employees | ~20 |Ticker | NASDAQ: IKT |
c-Abl Tyrosine Kinase Inhibition Inhibikase's platform targets the c-Abl tyrosine kinase pathway, which is activated in response to cellular stress in neurodegenerative diseases:
c-Abl activation : Elevated in PD brains, particularly in substantia nigra dopaminergic neuronsPathogenic mechanisms : Contributes to alpha-synuclein phosphorylation, mitochondrial dysfunction, and neuroinflammationTherapeutic rationale : Inhibiting c-Abl may protect neurons and slow disease progressionChemical Biology Approach The company uses structure-based drug design to develop brain-penetrant c-Abl inhibitors optimized for CNS delivery.
Clinical Pipeline
IkT-148009 (Lead Program) IkT-148009 is a potent, selective c-Abl tyrosine kinase inhibitor designed for once-daily oral dosing.
| Attribute | Details |Mechanism | c-Abl kinase inhibition |Target | Activated c-Abl in dopaminergic neurons |Phase | Phase 2 |Indication | Parkinson's disease |Administration | Oral (tablet) |Status | Enrolling |
Clinical Development
Phase 1 : Completed in healthy volunteers and PD patientsPhase 2 : Ongoing in patients with early-to-midstage Parkinson's diseasePrimary endpoints : Safety, tolerability, pharmacokineticsSecondary endpoints : Motor function (MDS-UPDRS), biomarker modulationRationale c-Abl activation contributes to Parkinson's disease pathology through multiple mechanisms: [@cabl2023]
Alpha-synuclein phosphorylation : c-Abl phosphorylates alpha-synuclein at Tyr127, promoting aggregationMitochondrial dysfunction : Impairs complex I activity and promotes mitophagy defectsNeuroinflammation : Activates microglia and promotes pro-inflammatory cytokine releaseNeuronal death : Direct contribution to dopaminergic neuron vulnerability
Preclinical Pipeline | Drug | Target | Indication | Stage |
Scientific Rationale
c-Abl in Neurodegeneration The c-Abl tyrosine kinase has emerged as a therapeutic target in neurodegenerative diseases:
Parkinson's Disease
Elevated c-Abl activity in substantia nigra of PD patients
Correlation with disease severity
Preclinical studies show neuroprotection with c-Abl inhibitors
Multiple System Atrophy (MSA)
c-Abl activation in oligodendrocytes
Contributes to alpha-synuclein pathology
IkT-148x being developed for this indication
Alzheimer's Disease
c-Abl implicated in tau pathology
Potential for disease modification
Clinical Results
Phase 1 Study
Population : Healthy volunteers and Parkinson's disease patientsDosing : Single and multiple ascending dosesResults :Good safety and tolerability
Dose-proportional pharmacokinetics
Target engagement (reduced phosphorylated alpha-synuclein in CSF)
Business Development
Partnerships
Academic collaborations : Partnerships with Parkinson's disease research centersCRO partnerships : Contract research organizations for clinical trial executionFuture plans : Seeking pharmaceutical partnerships for late-stage developmentFunding History | Year | Event | Amount |
Competitive Landscape Inhibikase is the leading c-Abl inhibitor in clinical development for Parkinson's disease:
| Company | Drug | Target | Status |
Related Pages
[Parkinson's Disease](/diseases/parkinsons-disease)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[LRRK2 Pathway](/mechanisms/lrrk2-pathway)
[PD Pipeline Companies](/companies/pd-pipeline-companies)
[Denali Therapeutics](/companies/denali-therapeutics)
[Voyager Therapeutics](/companies/voyager-therapeutics)
[c-Abl Tyrosine Kinase](/proteins/abl1-protein)
[Multiple System Atrophy](/diseases/multiple-system-atrophy)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Neuroinflammation](/mechanisms/neuroinflammation)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, Inhibikase Therapeutics Website (n.d.)
[Unknown, c-Abl in Parkinson's Disease (Nature Reviews Neurology, 2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37000000/)
Unknown, IkT-148009 Phase 1 Results (n.d.)
Pathway Diagram The following diagram shows the key molecular relationships involving Inhibikase Therapeutics discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Show full description